Introduction
============

Breast cancer (BC) is the most frequent tumor in women worldwide and although its mortality has significantly decreased in the past decades some tumors are still difficult to treat. Breast tumors can be categorized as luminal subtype A, luminal subtype B, HER-2^+^, basal subtype, normal breast-like, and the recently introduced Claudin-low subtype, based on their molecular characteristics.[@R1]^,^[@R2] In the clinical routine BC is classified based on specific immunohistochemical markers that define different phenotypes. Triple negative breast cancers (TNBC), neither expressing estrogen receptor (ER), progesterone receptor (PR) nor HER-2, accounts for 10--20% of BC and are among the most aggressive tumors yet without effective therapies.[@R3] TNBC has common features overlapping with basal-like molecular class of tumors and cancers carrying BRCA1 germ line mutation and in fact they are generally, but not constanly, of the basal subtype.[@R4] In addition, a subset of TNBC exists that also expresses vimentin. It is thought that this group represents BC that have undergone an epithelial-to-mesenchymal transition (EMT) and it has been associated to more invasive tumors, higher mitotic indexes, and worse clinical outcome.[@R5]^,^[@R6]

Metastasis is a hallmark of most tumor types and the cause of the majority of cancer deaths. BC first disseminates via lymphatic vessels to their regional lymph nodes (LN); the axillary LN status is one of the most important prognostic variables in BC and a crucial component of the staging system. Several clinico-histopathological parameters are considered to be strong predictors of metastasis; however, they fail to accurately classify breast tumors according to their clinical behavior and to predict which patients will have disease recurrence. Although the connection between LN metastases, poor prognosis and shorter survival is clearly established, the active involvement of the lymphatic system in cancer metastasis remains still largely unknown. TNBC has a propensity for visceral metastasis to brain, and lung, rather than to LN, bone or liver.[@R7] This could be due to a trend of TNBC cells to disseminate through blood vessels rather than lymphatic spread. However, the presence of LN metastasis in TNBC patients is significantly associated to shorter overall survival (OS) and recurrence-free survival in comparison to node-negative patients, although the prognosis may not be affected by the number of positive LN.[@R8]

Protein expression, including predictive markers like hormone receptors and HER-2 can change during disease progression from primary to metastatic BC.[@R9]^,^[@R10] Several reports have shown that a discordant status for HER-2 and hormone receptors can be found when paired samples of primary and metastatic BC are compared and that these discordances could have an impact in treatment response in metastatic BC patients which is now only based in the primary tumor phenotype. Therefore, reassessment of these markers at the time of disease progression may help to optimize and personalize treatment decisions.[@R11]^,^[@R12] In this sense, many other proteins may also change during tumor progression, conferring metastatic cells different abilities to grow, invade distant places, drugs resistance and angiogenesis, that could have an impact in treatment decision and success.

Metastatic tissue can be difficult to obtain in the clinical setting because of the location of metastatic site to be compared with the paired primary tumor. To study protein expression changes taken place throughout the metastatic progression we thought to use human TNBC cell lines. The human cell line IIB-BR-G was originated from a primary breast tumor that did not express ER, PR or HER-2 and was tumorigenic in nude mice after subcutaneous (s.c.) inoculation.[@R13] A spontaneous metastatic variant (IIB-BR-G-MT) was obtained after 40 subcutaneous passages in nude mice. Metastases that grew in LN were excised and xenografted subcutaneously twice to enrich the tumor population with metastatic cells. IIB-BR-G-~MTS~ cells generated tumors that increased their growth rates in vivo, gave rise to LN in 100% of recipients, some mice also presenting lung micrometastases as we have previously shown.[@R14]

In the present work we performed a proteomic characterization of the LN-metastasis-derived IIB-BR-G-~MTS6~ TNBC cell line~,~ selected after six rounds of metastatic enrichment in nude mice. We compared this cell line to the parental non-metastatic IIB-BR-G cell line, using an antibody-based protein array that allows primarily the screening of chemokines, cytokines, growth factors and their receptors, in order to identify protein expression changes that could be associated to their metastatic phenotype.

Results
=======

Description of IIB-BR-G and IIB-BR-G-~MTS6~ model
-------------------------------------------------

After various s.c. inoculation in nude mice, IIB-BR-G cells developed spontaneous metastases in the axillary LNs which were excised, cultured in vitro for a few passages and re-inoculated in nude mice s.c. After repeating this procedure for six times in order to enrich the population in metastatic cells, we generated IIB-BR-G-~MTS6~ cell line ([Fig. 1A](#F1){ref-type="fig"}). In vitro, both IIB-BR- and IIB-BR-G-~MTS6~ cell lines grew as monolayers, although IIB-BR-G-~MTS6~ cells tended to be less adhesive with a heterogeneous morphology and did not reach confluence as IIB-BR-G cells did. Their growth curves were also different since IIB-BR-G cells grew faster with a doubling time of 55.96 h while the growth of IIB-BR-G-~MTS6~ cells was slower (doubling time 85.62 h) ([Fig. 1B](#F1){ref-type="fig"}). However, anchorage-independent growth was significantly higher for IIB-BR-G-~MTS6~ cells as compared with IIB-BR-G as evidenced in soft agar clonogenic assays (p \< 0.0001) ([Fig. 1C](#F1){ref-type="fig"}).

![**Figure 1.** IIB-BR-G and IIB-BR-G-~MTS6~ TNBC cell lines. (A) IIB-BR-G-~MTS6~ cell line was obtained after six rounds of enrichment in metastatic cells to the LN, after initial s.c. injection of IIB-BR-G cells into nude mice. (B) In vitro tumor cell growth. IIB-BR-G and IIB-BR-G-~MTS6~ cell growth was assessed by the MTT method in quadruplicate. Results are shown as mean ± SD (C) Anchorage independent cell growth. Clonogenic assays for IIB-BR-G and IIB-BR-G-~MTS6~ were performed in triplicate. Data show the number of counted colonies as mean ± SD. \*\*\*, statistically highly significant, p \< 0.0001 (t-test). (D) In vivo growth curves. IIB-BR-G and IIB-BR-G-~MTS6~ were injected s.c. in nude mice (n = 5) and tumor volumes were measured during 9 and 6 weeks, respectively. Result is shown as mean ± SD. Histological analysis of xenografted tumors. IIB-BR-G (E) and IIB-BR-G-~MTS6~ (F) HE staining. (G) Vimentin immunohistochemistry in IIB-BR-G-~MTS6~ LN metastasis. (H) IIB-BR-G-~MTS6~ LN metastasis HE staining where an afferent lymph vessel containing a tumor emboli is shown. Scale bar = 20 µm.](cbt-13-1123-g1){#F1}

In vivo, IIB-BR-G-~MTS6~ s.c. tumors grew earlier and faster with a calculated doubling time of 6.8 d compared with IIB-BR-G tumors (doubling time 8.7 d) (p \< 0.0001) ([Fig. 1D](#F1){ref-type="fig"}). Five weeks after inoculation IIB-BR-G-~MTS6~ s.c. tumors have large central necrotic areas probably due to hypoxia generated by fast growth. The same phenomenon was observed but only after 19 weeks for IIB-BR-G cells (not shown).

IIB-BR-G and IIB-BR-G-~MTS6~ cells inoculated s.c. in the back or in the mammary fat pad developed tumors in all recipients (n = 5) and IIB-BR-G-~MTS6~ additionally developed metastases in axillary LN in 100% of mice by 5--6 weeks, while IIB-BR-G cells did not, even 19 weeks after inoculation (not shown). Metastases were evident macroscopically even in contralateral LN to the inoculated tumor. Metastasis to the LN was confirmed histologically after examination of hematoxylin-eosin stained sections ([Fig. 1E--H](#F1){ref-type="fig"}). In some IIB-BR-G-~MTS6~ bearing mice some micrometastasis to the lungs could also be found (not shown).

Proteomic analysis by antibody-based array comparing IIB-BR-G and IIB-BR-G-~MTS6~ cell lines showed an expression profile associated to metastasis
--------------------------------------------------------------------------------------------------------------------------------------------------

An antibody array using 174 antibodies distributed in three glass slides allowed us to test the relative expression of 168 different proteins secreted into CM and present in cell extracts of IIB-BR-G and IIB-BR-G-~MTS6~ cell lines. This antibody array was selected to test the expression changes of cytokines, growth factors and chemokines that could be related to the metastatic ability of IIB-BR-G-~MTS6~ cells relative to that of IIB-BR-G. All significantly deregulated proteins in IIB-BR-G-~MTS6~ compared with IIB-BR-G cells are shown in [Tables 1](#T1){ref-type="table"} and [2](#T2){ref-type="table"}, corresponding to secreted proteins into CM and present in cell extracts, respectively. The relative expression values for all tested proteins that remained unchanged (log~2~ relative expression IIB-BR-G-~MTS6~/IIB-BR-G between 1 and -1) are shown in [**TableS1 and S2**](#SUP1){ref-type="supplementary-material"}.

###### **Table 1.** Deregulated secreted proteins in IIB-BR-G-~MTS6~ CM compared with parental IIB-BR-G

  Name in Antibody Array   Gene Symbol   Description                                                    Log~2~ Fold Change
  ------------------------ ------------- -------------------------------------------------------------- --------------------
  IL-1 β                   IL1b          Interleukin 1, β                                               8.17
  GRO-α                    CXCL1         Chemokine (CXC motif) ligand 1                                 6.87
  MIP-3 α                  CCL20         Chemokine (c-c motif) ligand 20                                6.71
  IL-2 R α                 IL2RA         Interleukin 2 receptor, α                                      5.55
  IL-1 α                   IL1a          Interleukin 1, α                                               5.44
  IL-6                     IL6           Interleukin 6                                                  4.65
  IL-4                     IL4           Interleukin 4                                                  4.26
  MCP-2                    CCL8          Chemokine (c-c motif) ligand 8                                 3.19
  IL-8                     IL8           Interleukin 8                                                  2.63
  CXCL-16                  CXCL16        Chemokine (CXC-motif) ligand 16                                2.59
  GCP-2                    CXCL5         Chemokine (CXC-motif) ligand 5                                 2.42
  RANTES                   CCL5          Chemokine (C-C-motif) ligand 5                                 1.66
  NAP-2/CXCL7              CXCL7         Chemokine (CXC-motif) ligand 7                                 1.64
  PARC                     CCL18         Chemokine (CC-motif) ligand 18                                 1.36
  IL-18 BP α               IL18          Interleukin 18                                                 1.33
  sgp130                   IL6st         Interleukin 6 signal transducer (gp130, oncostatin receptor)   1.18
  TARC                     CCL17         Chemokine (CC-motif) ligand 17                                 1.15
  IL-18Rbeta               IL18RB        Interleukin 18 receptor β                                      -1.02
  I-TAC                    CXCL11        Chemokine (CXC-motif) ligand 11                                -1.18
  HCC-4                    CCL16         Chemokine (CC motif) ligand 16                                 -1.31
  IL-11                    IL11          Interleukin 11                                                 -1.43
  IL-1RI                   IL1R1         Interleukin 1 receptor, type I                                 -1.49
  MIG                      CXCL9         Chemokine CXC-motif                                            -1.73
  IL-12 p70                IL12          Interleukin 12                                                 -1.87
  IFN gamma                IFNG          Interferon, gamma                                              -2.1
  MIP-3 β                  CCL19         Chemokine (CC-motif) ligand 19                                 -2.43
  MIP-1 β                  CCL4          Chemokine (CC-motif) ligand 4                                  -4.49
  SDF-1 β                  CXCL12        Chemokine (CXC-motif) ligand 12                                -4.82

  -------------------------------------------------------------------------------------------------------------------------------------------------
  *Growth and differentiation factors, receptors and regulators*                                                                        
  ---------------------------------------------------------------- ----------- -------------------------------------------------------- -----------
  IGFBP-1                                                          IGFBP1      Insulin growth factor binding protein 1                  8.17

  GM-CSF                                                           CSF2        Granulocyte-macrophage colony stimulating factor         6.01

  G-CSF                                                            CSF3        Granulocyte colony stimulating factor                    5.92

  sTNF-RI                                                          TNFRSF1A    Tumor necrosis factor receptor superfamily,\             3.65
                                                                               member 1 A                                               

  PDGFAA                                                           PDGFA       Platelet derived growth factor A                         3.23

  IGFBP-6                                                          IGFBP6      Insulin growth factor binding protein 6                  3.18

  EGF-R                                                            EGFR        Epidermal growth factor receptor                         3.11

  LAP                                                              TGFB1       Tumor growth factor β 1                                  2.84

  IGFBP-4                                                          IGFBP4      Insulin growth factor binding protein 4                  2.30

  NT-4                                                             NTF5        Neurotrophic growth factor 4                             1.50

  IGFBP-3                                                          IGFBP3      Insulin growth factor binding protein 3                  1.41

  Osteoprotegerin                                                  TNFRSF11B   Tumor necrosis factor receptor superfamily, member 11B   1.11

  TRAIL R3                                                         TNFRSF10C   Tumor necrosis factor receptor superfamily, member 10C   -1.14

  Oncostatin M                                                     OSM         Oncostatin M                                             -1.19

  HGF                                                              HGF         Hepatocyte growth factor                                 -1.20

  BTC                                                              BTC         Betacellulin                                             -1.75

  FGF-9                                                            FGF9        Fibroblast growth factor 9 (glia-activating factor)          -3.86

  GITR-ligand                                                      TNFRSF18    Tumor necrosis factor receptor superfamily,\             -4.23
                                                                               member 18                                                
  -------------------------------------------------------------------------------------------------------------------------------------------------

  *Cell adhesion, angiogenesis and invasion related*                                                               
  ---------------------------------------------------- ----------- ----------------------------------------------- ----------
  VEGF                                                 VEGF        Vascular endothelial growth factor                  4.62
  Angiogenin                                           Ang         Angiogenin, ribonuclease, RNase A family, 5         4.56
  ICAM-1                                               ICAM1       Intercellular adhesion molecule 1               4.3
  BMP-7                                                BMP7        Bone morphogenetic protein 7                    4.21
  uPAR                                                 PLAUR       Urokinase-type Plasminogen activator receptor   4.17
  bFGF                                                 FGF2        Basic fibroblast growth factor                  1.81
  **TIMP1**                                            **TIMP1**   **metallopeptidase inhibitor 1**                **1.65**
  Activin A                                            INHBA       Inhibin A                                       1.38
  Tie-2                                                TEK         TEK tyrosine kinase endotelial                  -1.35
  MMP-13                                               MMP13       matrix metalloproteinase 13 (collagenase 3)     -3,06
  ICAM-3                                               ICAM-3      Intercellular adhesion molecule 3               -4.54
  VEGF-D                                               FIGF        Vascular endotelial factor D                    -5.83

  *Others*                                                      
  ----------- --------- --------------------------------------- -------
  Siglec-5    Siglec5   Sialic acid binding Ig-like lectin 5    -1.19
  CD14        CD14      Monocyte differentiation antigen CD14   -1.36
  Prolactin   Prl       prolactin                               -2.22
  Agrp        AGRP      Agouti related protein homolog          -3.4

Log~2~ fold change: Log~2~ of Positive Control Normalization without Background sample IIB-BR-G-~MTS6~/Positive Control Normalization without Background sample IIB-BR-G.

###### Deregulated proteins in IIB-BR-G-MTS6 cell extracts secreted compared with parental IIB-BR-G

  Name in Antibody Array   Gene Symbol     Description                                                      Log2 Fold Change
  ------------------------ --------------- ---------------------------------------------------------------- ------------------
  MIP-1 α                  CCL3            chemokine (c-c motif) ligand 3                                   8.9
  IL-2 Ralpha              IL2Ra           Interleukin2receptor, α                                          6.5
  GRO-α                    CXCL1           chemokine (c-x-c motif) ligand 1                                 6.1
  Acrp30                   Adipoq (APM1)   Adiponectin                                                      3.5
  IL-8                     IL8             interleukin 8                                                    2.4
  ActivinA                 INHBA           Inhibin, β A (activin A, activin AB α polypeptide)               2.4
  sgp130I                  IL6st           Interleukin 6 signal transducer (gp130, oncostatin M receptor)   1.8
  IL6-R                    IL6R            Interleukin 6 receptor                                           1.7
  MPIF-1                   CCL23           Chemokine (C-C motif) ligand 23                                  1.7
  IL-12p70                 IL12            Interleukin 12                                                   1.2
  ENA-78                   CXCL5           Chemokine(C-X-C motif) ligand 5                                  1.1
  IL-2 Rbeta               IL2RB           Interleukin 2 receptor, β                                        -2.1

  Growth and differentiation factors, receptors and regulators                                                                                                            
  -------------------------------------------------------------- ----------- ------------------------------------------------------------------------------------------- ------
  GCSF                                                           CSF3        Colony stimulating factor 3 (granulocyte)                                                   8.7
  PlGF                                                           PlGF        Placental growth factor                                                                     4.6
  TRAIL R4                                                       TNFRSF10D   Tumor necrosis factor receptor superfamily, member 10d, decoy with truncated death domain   2.4
  FGF-9                                                          FGF9        Fibroblast growth factor 9 (glia-activating factor)                                         2
  PDGF-AB                                                        PDGF        Platelet derived growth factor polypeptide                                                  1.6
  HGF                                                            HGF         Hepatocyte growth factor (hepatopoietin A, scatter factor)                                  1.2
  Tie-1                                                          TIE         Tyrosine kinase with immunoglobulin and epidermal growth factor homology domain             -1.2
  DR6                                                            TNFRSF21    Tumor necrosis factor receptor superfamily, member 21                                       -3.4
  uPAR                                                           PLAUR       Platelet/endothelial adhesion molecule 1                                                    2.8
  Tie-2                                                          TEK         TEK tyrosine kinase endotelial                                                              2.1
  ICAM-3                                                         ICAM3       Intercelular adhesion molecule 3                                                            2
  MMP-1                                                          MMP1        matrix metalloproteinase 1 (interstitial collagenase)                                       2
  MMP-13                                                         MMP13       matrix metalloproteinase 13 (collagenase 3)                                                 1.8
  MMP-9                                                          MMP9        Matrix metalloproteinase 9 (galatinase B, 92kDa gelatinase, 92kDa type IV collagenase)      1.2
  ICAM-1                                                         ICAM1       Intercelular adhesion molecule 1                                                            1.2
  PECAM-1                                                        PECAM1      platelet/endothelial cell adhesion molecule 1                                               1.2
  VEGFR2                                                         KDR         kinase insert domain protein receptor                                                       -1.9

  Others                                                       
  ---------- --------- -------------------------------------- ------
  SIGLEC-5   SIGLEC5   Sialic acid binding Ig-like lectin 5   -3.2

Log2 fold change: Log2 of Positive Control Normalization without Background sample IIB-BR-G-MTS6. Positive Control Normalization without Background sample IIB-BR-G.

The analysis of CM showed that IIB-BR-G-~MTS6~ secretion was higher for 37 proteins and lower for 27 while the other proteins remained unchanged. The most upregulated IIB-BR-G-~MTS6~ secreted proteins (CM) were IL1β, IGFBP1, GROα/CXCL1, MIP-3α/CCL20, GM-CSF/CSF3, GCSF/CSF2, IL2R α, IL1α, IL6 and VEGFA. Among the less secreted proteins we found VEGFD, SDF1-β/ CXCL12, ICAM3, MMP13, AgRP, IL12 p40, FGF9, GITR-Ligand and MIP-1β/CCL4.

For some proteins signal in the antibody array was negative for both cells lines (less than two times negative controls signal), such as L-selectin (expressed in neutrophils), NGF (nerve growth factor), IL-2Rγ, IP-10/CXCL10, secreted by monocytes and lymphocytes, TECK/CCL25, (expressed in small intestine and thymus) and CK β 8--1. Also, in CM of both cell lines some receptors like EGFR, IL2RA, were detected presumably shed into the CM or derived from dead cells.

With respect to cell extracts, IIB-BR-G-~MTS6~ showed upregulation of 24 proteins and downregulation of 6 compared with parental IIB-BR-G. The most upregulated proteins were MIP-1 α/CCL3, GCSF/CSF3, IL2Ra, CXCL1, PlGF and Adiponectin (APM1). Downregulation in IIB-BR-G-~MTS6~ was found for Siglec5, TNFRSF21, IL2Rb and VEGFR2 (KDR). No expression of NGF, IL1 R4/ST2, IL1R1, IL1R2, IL11, L-Selectin, IP-10 or IL2 Rγ, was observed for both cell lines.

We used EASE annotation tool to disclose the potential biological relevance of the differentially expressed proteins that could be related to the metastatic phenotype we used. Using Gene Ontology Annotation we identified some functional categories that were over-represented among the IIB-BR-G-~MTS6~ deregulated proteins recognized in the antibody array. [Table 3](#T3){ref-type="table"} shows the combined CM and cell extracts results of the EASE analysis. It also revealed that expression of proteins located in chromosome 7 is significantly altered in IIB-BR-G-~MTS6~ cells (p = 0.0069) since six of them located in 7p (EGFR, IGFBP1, IGFBP3, IL6, INHBA, PDGFA) and one in 7 q (HGF) have increased their expression in IIB-BR-G-~MTS6~ as compared with IIB-BR-G cells.

###### **Table 3.** Functional categories represented among deregulated proteins in IIB-BR-G-~MTS6~ vs IIB-BR-G

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Annotation Tool         Functional Category                           EASE\* Score   Protein
  ----------------------- --------------------------------------------- -------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------
  GO Biological Process   response to wounding                          9.07e-003      ↑IL1α; IL1β; IL4; IL8, CCL17; CCL18; CCL20; CCL23; CXCL5; CCL3; CCL5; CCL8; CSF2; CSF3; CXCL1;\
                                                                                       ↓ CCL16; CXCL11; CXCL12 CCL19; CXCL9; CCL4;

  GO Biological Process   cell growth and/or maintenance                7.82e-003      ↑CCL23; CCL3; CCL5; PDGFA; LAP-TGFβ1 TIMP1; CCL8;CSF3;CXCL1;CXCL5; EGFR; FGF2; FGF9; HGF; IGFBP1; IGFBP3; IGFBP4; IGFBP6; IL1α; IL1β; IL4; IL6; IL6R; IL8;\
                                                                                       ↓OSM; BTC; CCL19 CCL4; CXCL12 FIGF; IFNγ

  GO Biological Process   chemotaxis                                    2.37e-003      ↑ CCL17; CCL18;CCL20; CCL23; CCL3; CCL5; CCL8; CXCL1; CXCL12; CXCL5; CXCL9; FGF2; IL1α; IL4; IL8\
                                                                                       ↓ CCL16; CCL4;CCL19; CXCL11

  Organismal role         Cell migration/motility                       2.36e-003      ↑CCL17; CCL18; CCL20; CCL23; CCL3; CCL5; CCL8; CXCL1; CXCL12; CXCL5; CXCL9; FGF2; HGF; IFNγ; IGFBP3; IL4; IL8; PECAM1\
                                                                                       ↓CCL16; CCL19; CCL4 CXCL11

  GO Biological Process   response to stress                            4.11e-002      ↑CCL17;CCL20; CCL23; CCL3; CCL5; CCL8; CSF2; CSF3; CXCL1; CXCL11; CXCL12; CXCL5; CXCL9; IL1α; IL1β; IL4; IL6; IL8\
                                                                                       ↓CCL16; CCL18, CCL19, CCL4

  GO Molecular Function   glycosaminoglycan binding/heparin binding     2.92e-002      ↑CCL23; CCL3; FGF9

  GO Molecular Function   hydrolase activity/macromolecule catabolism   1.77e-002      ↑ANG; HGF; MMP1; MMP13; MMP9; TIMP1

  GO Biological Process   regulation of cell proliferation              1.56e-002      ↑CCL23; CCL3; CSF3; CXCL1; CXCL5; FGF2; TGFβ1-LAP; TIMP1; IGFBP6; IL1α; IL1β; IL6; IL8;\
                                                                                       ↓ OSM; BTC;FIGF

  GO Biological Process   inflammatory response/\                       1.47e-002      ↑IL1α; IL1β; IL8; CCL17; CCL18; CCL20; CCL23; CCL3; CCL5; CCL8; CXCL1; CXCL11; CXCL5;\
                          innate immune response                                       ↓CXCL12; CCL4CXCL9; CCL16; CCL19;

  GO Biological Process   cell-cell signaling                           1.29e-002      ↑CCL17;CCL20; CCL23; CCL3; CCL5; CCL8; CSF3; CXCL5; FGF2; IL1α; LAP-TGFβ1;IL1β; IL6; IL8; PDGFA\
                                                                                       ↓CCL16; CCL4; FGF9; IFNγ; CXCL11; CXCL9; CCL18; CXCL12; TEK
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Functional categories were obtained using EASE software as described under Methods. Results correspond to total deregulated IIB-BR-G-~MTS6~ proteins (up- and downregulated) combining cell extracts plus CM results. EASE scores \< 0.05 were considered significant. ↑ = protein upregulated in IIB-BR-G-~MTS6~ vs IIB-BR-G; ↓ = protein downregulated in IIB-BR-G-~MTS6~ vs IIB-BR-G.

To further investigate the biological relevance of genes that were up or downregulated in metastatic IIB-BR-G-~MTS6~ relative to primary tumor-derived IIB-BR-G we queried PubMed manually. Based on the potential function of BC cancer cells and their relationship with metastasis, we collected those deregulated proteins in IIB-BR-G-~MTS6~ cells that could be potentially associated to the metastatic ability and explored the previously published evidences. Grouped by their known role some of these proteins are briefly presented below along with results of additional experiments.

Proliferation and survival related proteins
-------------------------------------------

The oncogenic pathway EGFR-RAS signaling could have contributed to the autonomous cell proliferation in both cell lines as we have previously shown.[@R15] Through the antibody array assay several growth factors were found upregulated in the IIB-BR-G-~MTS6~ cells like CSF3, PlGF, CSF2, PDGF AA, PDGF AB, FGF2/bFGF, and the regulatory IGFBP1, 6, 4 and 3, as compared with non-metastatic IIB-BR-G. Some of these molecules could have a direct autocrine growth promoting effect but also could influence tumor stromal cells contributing to tumor growth. Also, IIB-BR-G-~MTS6~ cell secrete significantly more IL4 to CM (4.26 log~2~ fold change) than IIB-BR-G. Of note, despite its immune modulating activity IL4 has been shown to act as an autocrine survival factor in epithelial cancers.[@R16] Thus, production of some growth factors in metastatic IIB-BR-G- ~MTS6~ cells could be a relevant change in protein expression relative to IIB-BR-G cells, facilitating cells growth that could serve to explain faster in vivo growth of IIB-BR-G-~MTS6~ s.c. xenografts as compared with IIB-BR-G.

Angiogenesis and lymphangiogenesis related proteins
---------------------------------------------------

One critical event for tumor growth and metastasis is the generation of a new network of blood vessels that can be promoted by several cytokines produced by tumor or stroma cells. Several pro-angiogenic factors are upregulated in IIB-BR-G-~MTS6~ cells and /or secreted into their CM compared with non-metastatic IIB-BR-G cell line: CXCL1, IL8, IL1β, IL1α, VEGFA, angiogenin/ANG, HGF, PlGF, LAP-TGFβ1 (latent TGFβ1), FGF2/bFGF and TEK (tie2, angiopoietin receptor) ([Tables 1](#T1){ref-type="table"} and [2](#T2){ref-type="table"}). In vitro IIB-BR-G-~MTS6~ cells secreted much more vascular endothelial growth factor (VEGFA) to the CM but less VEGFD/FIGF. Both cell lines showed similar VEGFR3/FLT4 expression in cell extracts ([**Table S2**](#SUP1){ref-type="supplementary-material"}) but VEGFR2/KDR, was downregulated in IIB-BR-G-~MTS6~ cells ([Table 2](#T2){ref-type="table"}).

Since VEGFA is strongly upregulated in IIB-BR-G-~MTS6~ cells in vitro, and its expression has been associated to higher LVD,[@R17] we evaluated its expression in vivo by immunostaining of nude mice s.c. xenografts. As shown in [Figure 2](#F2){ref-type="fig"} both IIB-BR-G and IIB-BR-G-~MTS6~ tumors showed blood vessels and microvessels stained with an anti-VEGFA/B mAb and also tumor cells showed membrane staining. Some of the VEGFA/B expressing cells seemed incipient structures that could reflect neoangiogenesis or vasculogenic mimicry. The positive staining area in IIB-BR-G-~MTS6~ tumors was 2.99 times higher than in IIB-BR-G tumors (p = 0.044, t-test), evidencing higher VEGFA/B in vivo expression associated to the metastatic cells (not shown). Also, CD31 staining allowed us to evaluate the presence of blood vessels, microvessels and some positive cells without a definite structure distributed through the tumor ([Fig. 2](#F2){ref-type="fig"}). CD31 positive areas were thus quantified instead of blood vessel counts to better reflect angiogenesis. In this case, CD31 positive areas were 1.89 times higher in IIB-BR-G-~MTS6~ tumors compared with IIB-BR-G though in the limit of significance (p = 0.051, t-test).

![**Figure 2.** Angiogenesis related analyses. (A) VEGFA/B and CD31 stains were performed in IIB-BR-G and IIB-BR-G-~MTS6~ nude mice xenografts. An example of each immunostaining is shown for IIB-BR-G and IIB-BR-G-~MTS6~ xenografts. Also, an irrelevant mouse IgG was used as a negative control. Scale bar = 10µm. (B) VEGF A/B and CD31 positive stained areas were calculated for two different xenografts from each cell line as detailed under Methods. Results are indicated as mean ± SD positive area. \* Statistically significant p \< 0.05 (t-test).](cbt-13-1123-g2){#F2}

It has been demonstrated that activation of lymphatic endothelium by VEGFC is crucial for tumor cell entry and migration via lymphatic vessels. Anti-VEGFC mAb was not included in the selected antibody-array that we used, thus we measured its expression by qRT-PCR in IIB-BR-G and IIB-BR-G-~MTS6~ cell lines as well as in nude mice xenografts. As observed in [Figure 3A](#F3){ref-type="fig"} both cell lines express VEGFC, however, higher expression in metastatic IIB-BR-G-~MTS6~ tumors was found as compared with IIB-BR-G in vivo. As mentioned above, VEGFR3, the specific receptor for VEGFC was equally expressed by IIB-BR-G-~MTS6~ and IIB-BR-G cells.

![**Figure 3.** Lymphangiogenesis related analyses. (A) Relative VEGFC transcript abundances were measured by qPCR in tumor cell lines and xenografts as described under Materials and Methods. The expression fold changes were compared with the parental IIB-BR-G cell line or tumor, respectively. Results are mean ± SD of four biological replicates. \* Statistically significant p \< 0.05 (t-test). (B) LVD was calculated in Podoplanin stained sections of IIB-BR-G and IIB-BR-G-~MTS6~ xenografts as detailed under Methods. Dots represent each field count (Podoplanin-positive area /200x field), lines indicate the mean values. \*Statistically significant p \< 0.05 (t-test). C- Examples of Podoplanin stainings in xenografted tumors and the corresponding negative controls (Hamster IgG). Scale bar = 20 µm.](cbt-13-1123-g3){#F3}

Next, we evaluated the lymphatic vessel density (LVD) in IIB-BR-G-~MTS6~ and IIB-BR-G s.c. xenografts by immunostaining with anti-podoplanin, a specific marker of lymphatic endothelium. As observed in [Figure 3B](#F3){ref-type="fig"}, no significant differences in LVD were found between IIB-BR-G-~MTS6~ and IIB-BR-G tumors. In [Figure 3C](#F3){ref-type="fig"} examples of podoplanin immunostaining for both s.c. tumors are shown. In IIB-BR-G-~MTS6~, evaluation of LN metastasis with anti-podoplanin revealed many tumor cells located adjacent to lymphatic vessels and also emboli in the lumen of afferent lymph vessels evidencing lymphatic invasion ([Fig. 1H](#F1){ref-type="fig"}). Our results suggest that increase of pro-angiogenic and lymphangiogenic factors expression has occurred in IIB-BR-G-~MTS6~ cells after metastatic progression probably enabling tumor cells to generate more vascularized tumors and help facilitate tumor lymphatic invasion.

IIB-BR-G-~MTS6~ cells expression profile could be related to their higher in vitro invasiveness
-----------------------------------------------------------------------------------------------

IIB-BR-G-~MTS6~ cells exhibit higher expression of latency-associated peptide (LAP-TGFβ1) than IIB-BR-G, while other members of the TGFβ superfamily tested in the array, such as TGFβ1, TGFβ2, TGFβ3 and endoglin remained unchanged ([Table 1](#T1){ref-type="table"} and [**Tables S1 and S2**](#SUP1){ref-type="supplementary-material"}). TGFβ1 is synthesized as a large precursor molecule consisting of an N-terminal prodomain (LAP) and a C-terminal mature domain. LAP acts as a multifunctional peptide that extracellularly confers latency to TGFβ1.[@R18] TGFβ has opposite roles in BC cancer progression either acting as a tumor suppressor in the initial phase, or stimulating invasion and metastasis at later stages. It is known that TGFβ-induced invasion is related to metalloproteinases MMP2 and MMP9 expression.[@R19] Cell-associated MMP9 is upregulated in IIB-BR-G-~MTS6~ cells as compared with IIB-BR-G (log~2~ fold change 1.2, [Table 2](#T2){ref-type="table"}). We also validated MMP9 expression by zymogram using gelatin as a substrate and found that IIB-BR-G-~MTS6~ expressed more active MMP9 than IIB-BR-G cells ([Fig. 4A](#F4){ref-type="fig"}).

![**Figure 4.** Invasiveness related in vitro analyses. (A) MMP9 zymography was performed in serum-free CM from both cell lines using gelatin as a substrate and Coomasie Blue staining; the same samples were revealed in the presence of 20 mM EDTA to inhibit metalloprotease activity. A representative experiment is shown out of three independent determinations. (B) Number of cells that migrated through 8 µm membrane and invaded matrigel were counted using culture medium plus 10% FBS as chemoattractant. (C) Relative invasiveness for each cell line was calculated. Results are shown as mean ± SD.](cbt-13-1123-g4){#F4}

In an in vitro assay we tested both cellular migrations through 8µm pore filters and invasiveness using matrigel-coated filters. Although IIB-BR-G cells migrated more toward FBS (chemoatractant), IIB-BR-G-~MTS6~ cells showed higher matrigel invasion (p \< 0.05) ([Fig. 4B and C](#F4){ref-type="fig"}). IIB-BR-G-~MTS6~ cells showed more invasive ability in vitro which could be related to their higher expression of MMP9, MMP1, MMP13 and HGF that could facilitate matrigel degradation. Other upregulated molecule in IIB-BR-G-~MTS6~ cells is PLAUR (urokinase type plasminogen activator receptor) (2.8 log~2~ fold change) compared with IIB-BR-G. PLAUR is a key molecule for pericellular proteolysis in tumor cell invasion and metastasis.[@R20]

IIB-BR-G-~MTS6~ cell line expression profile suggests higher level of NFκB activation relative to parental IIB-BR-G cells
-------------------------------------------------------------------------------------------------------------------------

Several of the IIB-BR-G-~MTS6~ upregulated proteins correspond to gene products that are possible inducers of NFκB like GM-CSF, HGF, IL1 and also gene products regulated by NFκB like VEGF, IL6, IL8, MMP9 and MMP13. As a whole, this expression profile suggests a higher NFκB level of activation in IIB-BR-G-~MTS6~ than in IIB-BR-G, which could be related to their metastatic ability. NF-κB is a crucial factor that is implicated in oncogenic pathways and also regulates immunoinflam-matory responses. High level of activation of NFκB has been reported in specific subtypes of BC, particularly those tumors that express erbB2 and are ER negative[@R21] but tumors expressing EGFR (ErbB1) may also be equally dependent of competent NFκB.[@R22]

Cytokines, chemokines and metastasis
------------------------------------

In IIB-BR-G-~MTS6~ metastatic cells combining cell-associated and secretion to CM results, the more upregulated cytokines/chemokines were IL1β, CXCL1, CCL3, CCL20, IL1α, IL6, CXCL8/IL8, IL4, CCL8, CXCL16, and the less expressed were CXCL12, CCL4, CCL19 compared with the parental IIB-BR-G cell line ([Tables 1](#T1){ref-type="table"} and [2](#T2){ref-type="table"}). Chavey et al. reported that multiple cytokines were overexpressed in ER negative BC and correlated with the inflammatory cell content and aggressiveness of the tumors.[@R23] IL1β is the most over-secreted cytokine in IIB-BR-G-~MTS6~ CM vs IIB-BR-G and also IL1α is overexpressed. Of note, numerous in vitro and in vivo models have linked IL1β production to tumor cell migration, MMP9 and ICAM1 expression (both upregulated in IIB-BR-G-~MTS6~ cells compared with IIB-BR-G), angiogenesis and activation of NFκB signaling pathway.[@R24] Interestingly, IIB-BR-G-~MTS6~ cells CXCL12 (SDF-1) secretion is downregulated compared with IIB-BR-G non-metastatic cells. CXCL12 production has been associated to metastasis limitation by inhibiting CXCR4 signaling in melanoma, breast and colon cancer.[@R25]

EMT features in TNBC cell lines IIB-BR-G and IIB-BR-G-~MTS6~
------------------------------------------------------------

Of note, the basal like BC subtype-associated marker CX3CL1/fracktalkine is among the unchanged molecules expressed by both TNBC IIB-BR-G and IIB-BR-G-~MTS6~ cells. Also, we have previously shown that high vimentin expression is found in both cell lines by immunocytochemistry.[@R15] IIB-BR-G-~MTS6~ cells express much more PlGF than IIB-BR-G cells ([Table 2](#T2){ref-type="table"}), a known vimentin stabilizer.[@R26] In light of these results we confirmed that both cell lines expressed intermediate filament vimentin as detected by western blot ([Fig. 5A](#F5){ref-type="fig"}), but IIB-BR-G-~MTS6~ presented higher expression. This higher vimentin expression in IIB-BR-G-~MTS6~ cells was also confirmed by confocal microcopy (p \< 0.05) ([Fig. 5B](#F5){ref-type="fig"}) which also showed that both cell lines present highly organized actin F structures and that vimentin is mainly localized at cell extremes in IIB-BR-G-~MTS6~ cells which displayed a spindle-like morphology ([Fig. 5C](#F5){ref-type="fig"}). Moreover, with a 3D-topographical analysis and a plot-profile it was demonstrated that only IIB-BR-G-~MTS6~ cells present vimentin surrounded by microfilaments at these extremes. This observation could be due to the reorganization of actin cytoskeleton as the cell becomes motile, and which has been reported for other cancer cells.[@R27] E-cadherin was not expressed in both cell lines as determined by immunocytochemistry ([**Fig. S3**](#SUP1){ref-type="supplementary-material"}). Altogether these results suggest that IIB-BR-G-~MTS6~ cells have undergone a pronounced epithelial-to-mesenchymal-transition (EMT) probably associated to their metastatic behavior.

![**Figure 5.** EMT in IIB-BR-G and IIB-BR-G-~MTS6~ cells. (A) Presence of mesenchymal marker vimentin. Western Blot analysis was performed with cell extracts. A representative experiment is shown out of three independent determinations. Band intensities for vimentin were normalized to Histone H3; AU = arbitrary units. (B) Confocal microscopy of IIB-BR-G and IIB-BR-G-~MTS6~ staining with anti-vimentin mAb (red) and actin microfilaments (green); scale bar = 10 µm. The relative intensities per area unit are shown below; \*,statistically significant p \< 0.05 (t-test). (C) Spindle-shape morphology with cytoskeleton rearrangement determined by confocal microscopy as in B (top right), in IIB-BR-G and IIB-BR-G-~MTS6~. The left panels are showing a computer-generated 3D-Surface plot profile image at the level of the segments delimited by the white line. And the bottom right plot profiles show distribution of actin and vimentin at a single plane of these segments. Scale bar = 5 µm.](cbt-13-1123-g5){#F5}

Discussion
==========

Although a great number of molecules have been associated to BC metastasis the mechanisms used by tumor cells to achieve the metastatic cascade are still poorly understood. Over the last years a bulk of evidence suggests the existence of a complex interaction between tumor cells and the blood and lymphatic endothelium in which an important role of chemokines and cytokines is emerging,[@R28] sharing many similarities with leukocyte trafficking. Acting either in a paracrine manner to modulate the activity of surrounding cells or in an autocrine fashion, cytokines perform a wide variety of functions. Aberrant expression of cytokines has been implicated in tumor cell growth, survival, migration, invasion, angiogenesis and modulation of the immune system interaction with the tumor.[@R29]^,^[@R30]

The use of spontaneously metastatic human BC cell lines provides a promising model to investigate the metastatic process. Because of the complexity and heterogeneity of BC no single model would be expected to mimic all aspects of the disease. Thus, it is necessary to develop models to evaluate treatments for metastatic disease and to enhance our understanding of the mechanisms that underlie metastatic progression.[@R31] LN metastasis was modeled in nude mice by IIB-BR-G-~MTS6~ cells s.c. inoculation resulting in the spontaneous formation of LN tumors. Our findings showed incremented expression of multiple growth factors, pro-angiogenic /lymphangiogenic factors, metalloproteinases, chemokines and pro-inflammatory cytokines potentially relevant to the metastatic steps such as autocrine growth control, migration, interaction with stromal cells, angiogenesis, lymphangiogenesis and invasion. Despite TNBC has a propensity for visceral metastasis to brain, and lung, rather than LN, bone or liver,[@R7] since IIB-BR-G-~MTS6~ cells growing in nude mice were selected based on the generation of LN metastasis, their changes in protein expression relative to parental IIB-BR-G cells might be more related to this latter process. The scheme in [Figure 6](#F6){ref-type="fig"} represents a proposed model that integrates IIB-BR-G-~MTS6~ protein expression profile with the different steps of the metastatic cascade.

![**Figure 6.** Proposed model for IIB-BR-G-~MTS6~ cells metastatic behavior suggested by their expression profile. Metastatic IIB-BR-G-~MTS6~ increased their proliferation rate in vivo probably by upregulation of growth factors and/or their receptors (i.e., EGFR, PDGF, IL1β), increased several pro-angiogenic factors (i.e., IL8, VEGF, HGF, FGF2 and IL1β), and enhanced their EMT phenotype by autocrinous production of EMT inducers (i.e., IL6, PlGF, HGF, PLAUR and LAP-TGFβ). Cells could have acquired invasive capacity through MMPs secretion, and induced lymphangiogenesis by VEGFC secretion. Other upregulated proteins could presumably have a role in alteration of the tumor stroma, driven by hypoxia due to accelerated tumor growth, and immune cells recruitment to the tumor microenvironment. Altogether, these features might have facilitated metastatic dissemination of IIB-BR-G-~MTS6~ cells mainly to the LNs.](cbt-13-1123-g6){#F6}

We did not observe a discordant phenotype between IIB-BR-G and IIB-BR-G-~MTS6~ cells regarding hormonal status, HER-2 overexpression since both are TNBC as we have previously shown.[@R14] Also both cell lines express EGFR and have a mutated K-RAS status which could contribute to their autonomous cell proliferation and also to the modulation of gene expression to generate a tumor--promoting microenvironment.[@R14] EGFR-RAS activation has been shown to lead to increased secretion of IL8 and CXCL1 by tumor cells.[@R32] These chemokines in turn enhance tumor growth via an autocrine loop and promote tumor-associated angiogenesis. Despite this fact, we observed significant changes in other protein expression in IIB-BR-G-~MTS6~ metastatic cells as compared with IIB-BR-G. EGFR, IL8 and CXCL1 are among the most upregulated proteins compared with the non-metastatic IIB-BR-G. Besides, other differentially overexpressed growth factors and/or their receptors in IIB-BR-G-~MTS6~ (i.e., EGFR, FGF2/bFGF, PDGF, PlGF, LAP-TGFβ1) could have led to increased cell survival and proliferation, as evidenced by faster growth of IIB-BR-G-~MTS6~ vs IIB-BR-G xenografts in vivo.

IIB-BR-G-~MTS6~ upregulated IGFBPs 1, 3, 4 and 6. Deregulation of the IGF system is well recognized as a key contributor to the progression of multiple cancers including BC. Binding of IGFBP1 prolongs the half-life of the IGFs and alters their interaction with cell surface receptors. Interestingly, in pancreatic cancer, hypoxia has been shown to induce IGFBPs transcription contributing to reduce IGF signaling and to the survival of tumor cells.[@R33] Recent studies have demonstrated in MCF-7 breast cancer cells that IGF-I associates with vitronectin (VN) through IGFBP, and that IGF-I: IGFBP:VN complexes enhance cell migration and survival, processes central to metastasis.[@R34] During progression of BC extracellular matrix remodeling and a switch from estrogen dependence to EGFR dependence are accompanied by an increased expression of IGFBP3. IGFBP3 either inhibits or enhances EGF-mediated growth of breast epithelial cells, depending on the presence of fibronectin.[@R35] There is a number of reports suggesting that IGFBP3 can counterbalance IGFs effects. It has a negative effect on cell growth and survival.[@R36] This has led to the development of IGFBP3 as an anticancer therapeutic.[@R37] However, there are also many other reports that IGFBP3 can positively stimulate the proliferation[@R38] and survival[@R39] of various cells. In breast tumors the expression of IGFBP3 is positively associated with large, highly proliferative tumors and poor prognostic markers.[@R40]^,^[@R41] Thus, IGFBPs upregulation in IIB-BR-G-~MTS6~ cells could be associated to a lower IGF-signaling dependence for cell proliferation and survival and/or to the acquisition of a higher EGF-mediated metastatic growth in vivo.

FGF2/bFGF, upregulated in IIB-BR-G-~MTS6~ cells, has been very recently shown to promote the growth of TNBC in vitro and in vivo via an autocrine pathway that involves FGFR and thus points to a potential novel therapeutic approach using FGFR inhibitors for these tumors.[@R42]

IIB-BR-G-~MTS6~ s.c. tumors grow rapidly in nude mice and a central necrotic area is always observed by 5 weeks probably due to hypoxia (not shown). A hypoxic microenvironment often results in a milieu of pro-inflammatory and pro-angiogenic cytokines produced either by infiltrating cells and /or tumor cells. Since IIB-BR-G-~MTS6~ cells were selected in vivo, some of the proteins deregulated could reflect the interaction between fast growing tumor cells and an altered tumor stroma, as compared with IIB-BR-G slow growing tumors. Based on IIB-BR-G-~MTS6~ expression profile and recent publications,[@R43] we can speculate that an elevated IL1β, IL6 production, and NFκB activation, as well as the production of pro-angiogenic factors might have been induced in response to hypoxia and high ROS (reactive oxygen species) generation in the tumor and/or stroma.

Throughout the metastatic selection process IIB-BR-G cells have acquired the expression of several pro-angiogenic and lymphangiogenic factors that probably contributed to tumor vascularization, accelerated tumor growth and conferred tumor cells the ability to colonize the lymphatic system to settle as a LN metastasis. In this sense, upregulation of VEGFA, IL8, IL1, CXCL1, HGF, ANG and FGF2 altogether could have endowed IIB-BR-G-~MTS6~ cells with some of these pro-angiogenic properties. IIB-BR-G-~MTS6~ pro-angiogenic profile and VEGFA/B expression in s.c. nude mice xenografts suggest the existence of tumor cell vasculogenesis (vasculogenic mimicry), encircling solid tumor cells/nests, besides the existence of peripheral angiogenesis. Placenta growth factor (PlGF), a member of the VEGF family, is also upregulated in IIB-BR-G-~MTS6~ cells compared with IIB-BR-G. PlGF promotes metastasis, the mobilization and recruitment of hematopoietic precursors from bone marrow and enhances blood vessel maturation by acting on VEGFR1-expressing smooth muscle cells/pericytes.[@R44] In IIB-BR-G-~MTS6,~ higher CXCL1 and IL8 production could have directly increased blood and lymphatic endothelia proliferation, thus facilitating spread of tumor cells to LNs. Additionally, IL6 and IL4 production is commonly associated to a pro-angiogenic phenotype,[@R45] and consistently we observed their upregulation in IIB-BR-G-~MTS6~.

Lymphangiogenesis is an important step in tumor progression. Although the earliest feature of disseminated disease in BC is regional LN involvement, little is known about the mechanisms displayed by cancer cells to interact with lymphatic endothelial cells and enter the lymphatic system. VEGFC has been characterized as a lymphangiogenic growth factor signaling via VEGFR2 and VEGFR3. VEGFC has been detected on endothelial and tumor cells[@R46]^,^[@R47] and mediates tumor lymphangiogenesis and invasion of the neoplastic cells into lymphatic vessels. Similar to VEGFC, VEGFD is also a ligand of VEGFR2 and VEGFR3 but its role in lymph node metastasis in breast cancer is still controversial. VEGFA also acts as a lymphangiogenic factor, and tumor-derived VEGFA promotes expansion of the lymphatic network within draining sentinel LN, even before tumors metastasize.[@R47] In metastatic IIB-BR-G-~MTS6~ we found higher VEGFA in vitro while VEGFC expression was upregulated only in vivo, but lower VEGFD/FIGF, as compared with IIB-BR-G. Lymphatic invasion was evident in IIB-BR-G-~MTS6~ s.c. xenograft lymph node vessels and afferent LN vessels, although LVD in IIB-BR-G-~MTS6~ and IIB-BR-G s.c. tumors was not significantly different. Previously, high expression of VEGFA and C, but not of D, has been associated to higher LVD, higher MVD (microvessel density), the presence of LN metastasis, distant metastasis and a shorter OS in primary invasive breast tumors.[@R17]

The metastatic potential of chemokines is in part attributed to their ability to induce the expression of MMPs. It is believed that MMPs play a central role in the metastatic cascade and their increased expression reportedly is associated to the invasion and metastasis of various malignant tumors.[@R28] Our results further support their importance in the metastasic process in BC. Urokinase (uPA) and its receptor (PLAUR) overexpression are strongly correlated with poor prognosis in a variety of malignant tumors including BC.[@R48] PLAUR levels in breast tumors and tumor stroma are inversely correlated with ER status.[@R49] Also, under hypoxia, PLAUR has been shown to activate diverse cell signaling pathways that cooperatively induce EMT and may promote cancer metastasis.[@R50]^,^[@R51] Of note, PLAUR could also contribute to HGF cleavage to its active form, inducing cell invasiveness and enhancing tumorigenicity.[@R52] In IIB-BR-G-~MTS6~ cells MMP9, MMP2 and MMP13 are deregulated and PLAUR and HGF are also upregulated in comparison to IIB-BR-G cells.

Stromal contribution to tumor growth is considered as an important source of cytokines, growth and pro-angiogenic factors that help tumors to progress and metastasize. Some of the proteins overexpressed in IIB-BR-G-~MTS6~ have been described as expressed by stromal cells rather than by tumor cells, such as FGF2 production from CAF (cancer-associated fibroblasts), and extracellular MMPs.[@R28]^,^[@R53]

Metastatic IIB-BR-G-~MTS6~ most upregulated cytokine is IL1β as compared with IIB-BR-G. Secreted IL1β is strongly pro-inflammatory, potentiates tumor angiogenesis and the production of a network of invasiveness-promoting molecules as well as tumor-mediated suppression. In fact, it was shown that IL1 is frequently expressed in metastasis from patients with several types of cancer. IL1β is found expressed in most ER negative invasive BC and high serum levels correlated with patient's recurrence.[@R44]^,^[@R54] Alterations in IL1 genomic structure, patterns of expression and processing may have crucial effects in the oncogenic process. In some tumors IL1β also acts as an autocrine growth factor and various proteins induced by exogenous IL1β like MMPs, VEGF, FGF2, IL8 and MCP1 both in tumor and stroma cells,[@R55] are also coordinately upregulated in IIB-BR-G-~MTS6~ as compared with IIB-BR-G. IIB-BR-G-~MTS6~ secretes more IL1α to CM than IIB-BR-G cells. This fact is intriguing since IL1α is rarely secreted by other cells than macrophages and its expression in tumor cells is intracellular or membrane associated.[@R56] However, in melanoma, tumor secreted IL1α was shown to induce expression of pro-metastatic genes like IL6 and IL8 both in tumor and stromal cells.[@R57] Particularly in BC, IL1β is expressed in 90% of invasive carcinomas and in advanced tumors high IL1β content correlated well with parameters associated to tumors aggressiveness (ER negativity, p53 mutation, absence of bcl-2 and expression of pro-inflammatory cytokines). Our findings in metastatic IIB-BR-G-~MTS6~ cells further support that IL1β manipulation in TNBC tumors could be an attractive target for cancer therapy research.

In our TNBC metastatic model, CXCL12 production may prevent LN metastasis since it was found downregulated in IIB-BR-G-~MTS6~ as compared with parental IIB-BR-G cells. CXCL12 is a highly pleiotropic chemokine that has been implicated in the progression and site-specific metastasis of various cancers, including BC. Indeed, CXCL12 silencing has been shown to induce metastasis of breast and colon cancer cells and administration of CXCL12 has been proposed as a potential therapy to inhibit metastatic dissemination.[@R24]^,^[@R25] IIB-BR-G-~MTS6~ cells injected in nude mice occasionally established in the lungs as small tumor emboli (data not shown) and we have not yet analyzed their possible metastasis to bone. Several factors that could potentially contribute to bone metastasis are significantly upregulated in IIB-BR-G-~MTS6~ cells and/ or secreted into their CM, such as the known osteoclast activators CSF3, CSF2, TNFSF11 (RANKL), LAP-TGFβ1, IL6, MMP13 and IL8.[@R58] Thus, during LN metastasis progression BC cells might also acquire the ability to further disseminate and colonize other distant sites like bone.

CCL20/MIP-3α, a chemokine involved in the attraction of immature dendritic cells (DC) and their precursors, is among the five most upregulated proteins secreted into IIB-BR-G-~MTS6~ CM as compared with IIB-BR-G. Only few reports have suggested a possible relationship between CCL20/ MIP-3α and BC metastasis. It has been reported that adipocyte culture medium stimulates invasiveness of MDA-MB-231 cell via CCL20 production.[@R59] It could be possible that CCL20 production by IIB-BR-G-~MTS6~ cells could confer increased invasiveness without the requirement of adipocytes in the tumor environment.

Most tumors secrete immunosuppressive cytokines such as TGFβ, IL10 and VEGF.[@R60] In both cell lines we found IL10, IL4, LAP-TGFβ1, MMP9, and VEGF expression, suggesting that in vivo tumors generated by IIB-BR-G and specially IIB-BR-G-~MTS6~ cells, could create an immunosuppressive microenvironment favoring tumor growth and metastatic dissemination.[@R61]

IL8 recruits immune system cells to the tumor stroma that could contribute to an increase in angiogenesis in vivo, and tumor growth. There is a co-regulation of IL8, CXCL1, CXCL3, CXCL5 and CXCL6 since their coding genes are located in chromosome 4q21, in a cluster that has a coordinated expression pattern,[@R62] as we observed in IIB-BR-G-~MTS6~ cells. Secreted IL8 and CXCL1 activate endothelial CXCR1/2 receptors in a paracrine manner to cause robust endothelial cell proliferation, tube formation, and migration.[@R63]

Epithelial cells can acquire mesenchymal characteristics including flattened morphology and expression of vimentin filaments, a process named epithelial-to-mesenchymal-transition. EMT also leads to the acquisition of an invasive phenotype enabling cell migration into a new microenvironment and their differentiation into distinct cell types, allowing tumor progression and metastasis.[@R64] Several soluble factors and receptors that are potential inducers of EMT are expressed by these cells lines, and some are upregulated in IIB-BR-G-~MTS6~ cells, such as LAP- TGFβ, IL6, FGF9, HGF, EGF, MMP1, MMP9 and MMP13, as well as PLAUR. In order to extent its cytoplasm and/or to form invadopodia, the cell needs the active motility of intermediate filaments, as it has been determined for neurons, being the intermediate filaments which determine protrusions caliper.[@R65] Thus, IIB-BR-G-~MTS6~ cells expressing higher vimentin content could correlate with a more invadopodial phenotype than IIB-BR-G cells.

After global gene expression studies five molecular subtypes of BC have been identified (Luminal A, Luminal B, Her-2-enriched, Basal-like and Claudin-low), each of them presenting unique biologic features and different prognosis.[@R2]^,^[@R66] Most TNBC are of the basal like or Claudin-low subtypes. Claudin-low BC are of poor prognosis, enriched in tumor initiating cells (CD44^high^/CD24^low^) but show low or absent expression of genes involved in cell-cell junction, including claudin 3, 4 and 7 and E-cadherin. Also Claudin-low tumors are highly enriched in immune-related genes like IL6 and CXCL2 but express low levels of proliferation related genes like Ki67. Basal-like breast tumors instead show high mitotic index (Ki67^+^), high EGFR expression and are often chemotherapy responsive.[@R67] Both subtypes show significant features of EMT.

Based on their proteomic profile, IIB-BR-G and the metastatic derived IIB-BR-G-~MTS6~ cells could represent a model of aggressive TNBC which have undergone significant EMT, since they show: (1) a lack of expression of hormone receptors, (2) a high expression of vimentin, Fracktalkine/CX3CL1 and EGFR, (3) an expression of IL6, LAP-TGFβ and MMPs, (4) a high motility and invasive capacity, (5) lack of E-Cadherin expression, (6) in case of IIB-BR-G-~MTS6~ cells, fast tumor growth, a high in vitro invasiveness and metastatic ability in nude mice. Also, we have previously shown that these cells do not express cytokeratins 5/6, a feature that is found in most basal-like BC type tumors.[@R14] However, lack of E-Cadherin expression, high vimentin expression, pronounced EMT and expression of multiple immune related cytokines could also reflect the Claudin-low phenotype. Since we have not addressed claudins expression in this study we cannot truly define whether these cell lines represent basal like or Claudin-low TNBC.

In this study we report the development of a reproducible model to study the biology of human TNBC metastasis to LN in comparison with the parental non-metastatic cells. We succeeded in isolating a variant line with enhanced metastatic properties as demonstrated by a battery of assays.

We showed that IIB-BR-G-~MTS6~ metastatic cells exhibited significant protein expression changes as compared with the parental non-metastatic cell line and have different phenotypic characteristics associated to their metastatic behavior, probably reflecting changes that occurred during progression from primary tumor growth and metastatic dissemination.

The up- and downregulation of proteins in IIB-BR-G-~MTS6~ cells suggest interesting candidates for further investigation in TNBC metastasis. These cell lines offer an in vivo model which should facilitate in-depth studies to understand the features of TNBC progression, the interaction of metastatic TNBC cells with host microenvironment and to test potential targets for biologically-based new therapies for TNBC.

Materials and Methods
=====================

IIB-BR-G-~MTS6~ cells generation
--------------------------------

We generated IIB-BR-G-~MTS6~ cell line after s.c. inoculation of 1 × 10^6^ cells of IIB-BR-G-MT2 cell line,[@R14] either in the mammary fat pad or in the back of 8 week old female mice N:NIH(S)-Fox1nu (Bioterio Universidad Nacional de La Plata, Argentina). After excision of LN metastasis, separation of tumor cells, amplification in few culture passages and s.c. re-inoculation in nude mice were performed. This procedure was repeated four times to enrich the tumor population with metastatic cells. In total, after six rounds of enrichment IIB-BR-G-~MTS6~ cell line was obtained, amplified in culture to conform a stock and used for further experiments ([Fig. 1A](#F1){ref-type="fig"}). Animals were maintained in a special facility in a ventilated Rack provided with HEPA filtered air in an Animal Facility at the Fundación Instituto Leloir-IIBBA (CONICET), in accordance with the guidelines of the NIH (Guide for the Care and Use of Laboratory Animals, 1996). The authors have received permission from the Institutional Animal Care and Use Committee for the nude mice experiments.

Cell growth in vitro
--------------------

IIB-BR-G and IIB-BR-G-~MTS6~ cell lines were grown as previously described.[@R14] Cell growth curves were performed in quadruplicate by the MTT assay as previously described.[@R68] Anchorage independent growth ability was estimated in triplicate by the soft agar clonogenic assay as previously described. 5 × 10^3^ tumor cells were seeded and colonies were counted under an Olympus CKX41 microscope (Olympus) after 21 d culture.

Cell growth in vivo
-------------------

IIB-BR-G and IIB-BR-G-~MTS6~ cells (1 × 10^6^/0.1 ml phosphate buffered saline (PBS)) were injected s.c either in the mammary fat pad or the back of 8-week-old female nude mice. The tumors major and minor axes were measured with a caliper once a week. The tumor volumes were calculated using the formula: A^2^xB/2 where A = minor axis and B = major axis. Mice were euthanized with carbon monoxide; tumors were excised and samples were either formalin fixed or stored fresh at -80°C with RNAlater (Ambion) for RNA and protein extraction.

Antibody-based protein array
----------------------------

The expression of 168 proteins was tested simultaneously with a glass chips based Human Cytokine Antibody Array System G (RayBio Series G-2000 Series, slides VI, VII and VIII, AAH-CYT-G2000--8, RayBiotech) following the manufacturer's protocol. Protein extracts and serum-free conditioned medium (CM) from either IIB-BR-G or IIB-BR-G-~MTS6~ cell lines, were prepared following the manufacturer's protocol. Cell pellets were extracted with lysis buffer for 30 min and protein concentration was estimated by Bradford's method.[@R69] CM was collected after 24h culture of exponentially growing cells in serum-free culture medium. Briefly, after blocking the glass chips were incubated with cell extracts (100 µg total protein) or non-diluted CM (100 µl) overnight at 4°C. After washing steps chips were incubated with the corresponding biotin-conjugated antibodies for 2 h at room temperature (RT) and then washed four times. Finally, slides were incubated with fluorescent dye-conjugated streptavidin for 2h at RT in the dark and then washed. After complete drying the slides were scanned with an Axon Confocal Laser Scanner (GenePix 4000B, Axon Instruments) and images were processed with GenePix Pro 5.0 software.

Data processing and analysis
----------------------------

Data were normalized to positive controls of each slide with the RayBiotech Analysis Tool (RayBiotech) and relativization was performed after local background correction and substraction for each of the three slides. Each protein was tested in duplicate and median signal values 2-fold above negative controls were considered positive. Fold-change in expression was calculated as log~2~ of signal IIB-BR-G-~MTS6~/signal IIB-BR-G. The threshold of significant difference in fold-change for each protein was considered as log~2~ signal IIB-BR-G-~MTS6~/signal IIB-BR-G \> 1 or \< -1, meaning that the protein is more than two times up or downregulated in IIB-BR-G-~MTS6~ as compared with IIB-BR-G cells, respectively. Values between 1 and -1 were considered unchanged protein expression.

EASE software (DAVID, The Database for Annotation, Visualization and Integrated Discovery) was used to identify main gene categories differentially expressed by IIB-BR-G-~MTS6~ cells in comparison with IIB-BR-G. Ease scores \< 0.05 were considered significant. We also searched PubMed manually to investigate the biological relevance of genes that were up- and down- regulated.

Immunostaining
--------------

Formalin-fixed, paraffin-embedded sections were prepared with IIB-BR-G and IIB-BR-G-~MTS6~ cell pellets and/or tumor sections (4µm) and stained using the following primary mAbs: mouse anti-human VEGF (A and B) (a kind gift of Dr Alberto Baldi, IByME, Buenos Aires, Argentina), mouse anti-human E-cadherin (clone NCH-38, Dako), mouse anti-human CD31 (clone JC70, Cell Marque) (both evaluated with an irrelevant mouse IgG (Sigma) as a negative control) and hamster anti-mouse Podoplanin/gp36 (Abcam) (Hamster IgG as negative control). Immunostaining pretreatments consisted of sample dehydration in graded alcohols, enzyme digestion, or other heat mediated retrieval methods. Sections were stained using either Envision labeled polymer-HRP K4003 (Dako) or ABC system (Vectastain Universal Elite ABC kit, PK-6200, Vector Laboratories) and counterstained with hematoxylin.

Indirect immunofluorescence assays
----------------------------------

Cells grown on poly-lysine-coated coverslips were fixed with 4% paraformaldehyde and permeabilized with 0.1% triton X-100 in PBS. Fluorescence microscopy was performed in a LSM10 Meta confocal microscope (Carl Zeiss). Image analysis for immune localizations was performed using the 3D-surface plot plug-in of the Image-J program (v.1.42) from the NIH. Signal quantification and cytoplasmic redistribution were analyzed as previously described.[@R70] The reagents used were monoclonal IgM anti-vimentin (ascites) from Sigma Chemical Co., phalloidin-labeled microfilaments from Molecular Probes and Hoechst (Sigma).

Western blotting
----------------

Samples were lysed with 50 mM TRIS-HCl (pH 7.5), 5 mM EDTA, 150 mM NaCl, 1% NP-40, 0.1% SDS, in presence of Protease Inhibitor Cocktail (Sigma) for 30 min on ice. Protein extracts were obtained after centrifugation at 8,000x g for 10 min at 4°C and total protein concentration was measured by the Bradford assay. Thirty micrograms protein extracts were loaded onto 10% SDS-PAGE gels. Proteins were transferred onto nitrocellulose membranes (Sigma), blocked with 3% dried skim milk in PBS and then incubated with anti-vimentin mAbs (Clone VI-01, Abcam) and an anti-Histone H3 mAb (clone A3S, Upstate) (Sigma) overnight at 4°C. Binding of the mAbs was revealed using Alkaline Phosphatase (AP)-conjugated goat F(ab)'~2~ anti-mouse IgG(H^+^L) (Jackson Immunoresearch). Color development substrate was 5-bromo-4-chloro-3-indolyl-phosphate/nitro blue tetrazolium (NBT/BCIP) (Promega).

qPCR for VEGFC determination
----------------------------

RT-PCR was performed with the isolated total RNA (1 μg). RT-PCR was performed with using 5 ng random primers and the cDNA was synthesized using 200 units of MMLV-Reverse Transcriptase (Promega) at 37°C for 60 min. Real time PCR analysis was performed using specific primers designed to target unique regions of the cDNA. PCR runs were performed using SYBR Universal Master Mix (Applied Biosystems), and relative expression levels were determined by the ΔΔCt method using β-actin gene expression to normalize all samples. Both melting curve analysis and gel electrophoresis assessment were used to confirm the specificity of PCR reactions. The following cycling parameters were used: denaturation 95°C (1 min), annealing 56°C (1 min), extension and detection 72°C (30 sec). The cycler software was used for quantification of VEGFC mRNA levels relative to β-actin mRNA expression. Primers for VEGFC: forward 5′CCTCAGCAAGACGTTATTTGAAATT3′ and reverse 5′TGGCAAAACTGATTGTTACTGGTT3′; for β-actin: forward 5′CCAGAGGCGTACAGGGATAG3′ and reverse 5′CCAACCGCGAGAAGATGA-3′.

In vitro migration and invasion assay
-------------------------------------

In vitro migration and invasion assays were performed using 8 μm pore polycarbonate membrane transwells (BD Biosciences). For migration assay uncoated membranes were used while for invasion assay membranes were coated with 5μg/ml Matrigel (BD Biosciences). Cells were seeded in the upper chamber (5 × 10^4^ cells/well) in serum-free culture medium and incubated at 37°C for 4h. Culture medium plus 10% fetal bovine serum (FBS, Natocor) was used as chemoattractant. Following incubation, the medium was discarded from the upper chamber and the entire insert plate was removed for staining procedures. Membranes were fixed with cold methanol, stained with Giemsa and mounted onto glass slides with Canadax. Cells were counted under the microscope. Five 200 × fields/condition and three wells/condition were analyzed. Results are expressed as in Equation 1:

Zymography of matrix metalloproteinases using gelatin substrate
---------------------------------------------------------------

Condition media were obtained incubating 5 × 10^5^ cells of each cell line in 1.5 ml DMEM for 24hs. The media were then collected and stored at -80°C until assayed. To analyze the expression of metalloproteinases gelatin zymography was performed as previously described.[@R71] Briefly, 15µl conditioned medium (CM) from IIB-BR-G and IIB-BR-G-~MTS6~ cells were fractionated in 10% native PAGE containing 0.1% gelatin as substrate. After electrophoresis, gels were incubated for 1h at RT in Triton X-100 renaturing buffer and subsequently overnight at 37°C in developing buffer to allow enzymatic degradation of gelatin. The same assay was performed in the presence of 20 mM EDTA to inhibit the enzymatic reaction. After washing, the gels were stained with 0.125% Coomasie Brilliant Blue staining buffer and subsequently destained to visualize degradation bands. Molecular weight markers were used to determine the size of active enzymes. Pictures were documented with a trans-illuminator and a digital camera and the area of digestion was quantified using Image-J program (v.1.42) from the NIH software.

Angiogenesis and lymphangiogenesis analysis in vivo
---------------------------------------------------

Sections were examined by optical microscopy (Olympus BX40) and pictures were captured with 400× magnification (Olympus Digital Camera DP72). To quantify VEGFA/B, CD31 and Podoplanin stainings at least 5 representative pictures from IIB-BR-G or IIB-BR-G-~MTS6~ xenografts (n = 5) were analyzed using Fiji software. After setting the positive staining threshold, total positive areas were calculated for each picture.

To avoid duplications, the observation was made in a greek embroidery fashion. To separate immunostaining (brown stain) from hematoxylin staining (blue stain) the Color Threshold plug-in was applied. Images were then transformed into an 8-bit gray scale TIFF format. The number of stained structures was then counted. Data values obtained from at least 10 images of each slide were exported to a spreadsheet in order to perform the statistical analysis.

Statistics
----------

Comparisons between IIB-BR-G and IIB-BR-G-~MTS6~ were analyzed using Student's t-test to determine the p-values. p \< 0.05 was considered significant.
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